Tommy Alain

Oncolytic reovirus against ovarian and colon cancer.

Reovirus therapy of lymphoid malignancies.

Lymphomas and oncolytic virus therapy.

Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo.

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Proteolytic disassembly is a critical determinant for reovirus oncolysis.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Susceptibility of mantle cell lymphomas to reovirus oncolysis.

Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.

p53-dependent translational control of senescence and transformation via 4E-BPs.

The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing.

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs.

Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters.

Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.

IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.

Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.

Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E.

Distinct perturbation of the translatome by the antidiabetic drug metformin.

A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development.

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.

Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex.

Control of translation and miRNA-dependent repression by a novel poly(A) binding protein, hnRNP-Q.

Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling.

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.

Control of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinase.

Multifaceted regulation of somatic cell reprogramming by mRNA translational control.